TAXEL-CSC 80mg/2ml in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
operable node- positive breast cancer
operable node- negative breast cancer
For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer
